



Meeting Notice

ND Medicaid Drug Utilization Review Board Meeting

Wed., Sept. 2, 2015

1 p.m. (CT)

Pioneer Room - Ground Floor - Judicial Wing - State Capitol
600 E. Boulevard Ave.

Agenda

1. Administrative items

- Travel vouchers

2. Old business

- Review and approval of minutes of 06/15 meeting
- Budget update
- Review top 15 therapeutic categories/top 25 drugs
- Second review cholesterol lowering drugs
- Second review of injectable anticoagulants
- Second review of Akynzeo
- Second review of Nuessa
- Second review of Cholbam
- Update on drugs added to > \$3,000 prior authorization (Natpara)

3. New business

- Sanford Health Plan expansion update
- Prior authorization updates on current drugs/classes
- Review of Movantik (naloxegol)
- Review of Marinol (dronabinol)
- Review of skin pigment products (hydroquinone)
- Review of inhaled corticosteroid/long-acting beta-2 adrenergic agonist combination products (budesonide/formoterol, fluticasone/vilanterol, fluticasone/salmeterol, mometasone/formoterol)
- Review of medications used to treat irritable bowel syndrome (eluxadoline, linaclotide, lubiprostone)
- Review of medications used to treat ulcerative colitis (balsalazide, mesalamine, olsalazine, sulfasalazine)
- Review of sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin, empagliflozin)

3. New business (Continued)

- Review of immediate release oxycodone
- Review of immediate release narcotics used in conjunction with immediate release narcotic combinations
- Review of inhaled anti-infectives for cystic fibrosis (tobramycin, aztreonam)
- Review of leukotriene modifiers (montelukast, zafirlukast, zileuton)
- Gabapentin update
- Criteria recommendations
- Upcoming meeting date/agenda

4. Adjourn

Date Posted: Aug. 4, 2015